Harvard Bioscience Inc.

Harvard Bioscience closed Monday trading up more than 10% after the Holliston biotech released a strategic action plan and financial targets through 2021.

Harvard Bioscience opened the stock market on Friday trending up more than 20% after its second-quarter earnings reflected an improved financial condition as the company focuses on improving its underlying performance. 

Holliston life science equipment manufacturer Harvard Bioscience has replaced President and CEO Jeffrey Duchemin with four-year director James Green. 

The top executive for sales at Holliston life science researcher Harvard Bioscience has resigned during an overhaul of the company's sales team to focus on areas with higher growth potential, according to regulatory filings.

<i>(UPDATED Friday, July 31 to correct company name)</i> Holliston-based Harvard Bioscience reported Thursday that the second quarter of 2015 saw revenue rise to $28.8 million.

There is a science to the work of Harvard Bioscience CEO Jeffrey Duchemin. And acquisitions are an...

Harvard Bioscience of Holliston reported a $1.4 million loss amid lower first-quarter revenues of $25.8 million, a slight drop of about 0.5 percent from $25.9 million in the same period of 2014, the life sciences manufacturer said.

The CEO at biotech firm Harvard Apparatus Regenerative Technology (HART) of Holliston has resigned, replaced on an interim basis by CFO Thomas McNaughton, the company announced.

Holliston-based Harvard Apparatus Regenerative Technology, or HART, reported Thursday that the company had revenue of $45,000 in the fourth quarter of 2014 from the sale of bioreactor systems for organ regeneration research. That was more than double the $22,000 in revenue for the same period in 2013.

Harvard Bioscience of Holliston reported record quarterly revenues of $30.4 million in the fourth quarter of 2014.